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Erratum to ‘‘Relative therapeutic index between
inhaled formoterol and salbutamol in asthma
patients’’ [Respiratory Medicine 96(6) 412^417]$The publisher regrets that Appendix A appeared
incorrectly in theprinted issue and shouldhave appeared
as:
APPENDIXA
A parametric model was ¢tted to data in order to
estimate the relative therapeutic index between
formoterol and salbutamol. The dose response curves
for formoterol and salbutamol were assumed to be
parallel. Individual minimum SK+ andFin accordance
with the basic assumption of multiplicity for the relative
increase in FEV1Flog (Maximum FEV1) for all doses
were analyzed simultaneously as functions of the
logarithms of formoterol and salbutamol doses. The
parameters of the model (Model 1) were assumed to be
normally distributed random variables within the group
of investigated patients and the within-patient variation
was assumed to be independent for SK+ and FEV1.
The model was ¢tted to the data using theVonesh-Car-
ter method (21). Period e¡ects were adjusted for using a
¢xed e¡ect model and baseline di¡erences were
adjusted for using baseline as covariate for the placebo
e¡ect.
Model1
Minimum S Kþ
¼
a1; placebo;
a1 1 11þeðb1ðc1logðDoseÞÞ
 
; formoterol;
a1 1 11þeðb1ðd1logðDoseÞÞ
 
; salbutamol;
8><
>>:
logðMaximumFEV1Þ
¼
a2; placebo;
a2 þ b2 ðlogðDoseÞ þ c2Þ; formoterol;
a2 þ b2 ðlogðDoseÞ þ d2Þ; salbutamol:
8<
:$PII of original article: S0954-6111 (02) 00054-9Model parameters
a1 minimum SK+ after placebo
b1 Hill factor (curve shape)
c1 log (dose of formoterol causing suppression of
minimum SK+ to 50% of placebo)
d1 log (dose of salbutamol causing suppression of
minimum SK+ to 50% of placebo)
a2 log (Maximum FEV1) after placebo
b2 slope factor
c2 potency factor for formoterol (horizontal loca-
tion of the dose response line)
d2 potency factor for salbutamol (horizontal loca-
tion of the dose response line)
The relative dose potency was estimated as eðd1c1Þ
for SK+ and as eðc2d2Þ for FEV1.Therelative therapeutic
index was estimated as eððc2d2Þðd1c1ÞÞ. Con¢dence in-
tervals for the estimate were calculated using the
asymptotic normality of the estimates.
